Company intelligence / Profile preview
Acrivon Therapeutics, Inc.
Watertown, Massachusetts, United Statesacrivon.com ↗
- Ownership
- Public · ACRV
- Employees
- ~70
- Development stage
- Other
01
Overview
Acrivon's lead candidate, ACR-368 (prexasertib), a selective small molecule inhibitor of CHK1/CHK2, has shown promising results in a registrational-intent Phase 2 trial. The company reported a confirmed objective response rate of approximately 50% in ovarian and endometrial cancers using its OncoSignature biomarker test to select patients. All responders remained on treatment at the time of reporting and median duration of response had not been reached. The company’s AP3 platform enables precise patient selection beyond genomics by matching drug mechanism to tumor biology[8][10].
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
In-license agreement with Eli Lilly for prexasertib; open to strategic co-development partnerships around AP3 and OncoSignature tests[10]
04
Financials
- Market cap
- $67.3M
- Total revenue
- $0
- Enterprise value
- $-20.6M
Beyond the preview
Go deeper on Acrivon Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Acrivon Therapeutics, Inc..